Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 SAD study of BPL-003 in healthy subjects
NCT05347849Phase 1Completed
- Sponsor
- Beckley Psytech
- Start
- Feb 2022
- Primary completion
- Jan 2024
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in treatment-resistant depression (TRD) and alcohol use disorder (AUD) comparing BPL-003 arm with Placebo arm (2 arms). Primary endpoint: Percentage of subjects with treatment emergent adverse events at 65 days. Started Feb 2022; status: completed.
02
Drugs
mebufotenin
03
Conditions
treatment-resistant depression (TRD)alcohol use disorder (AUD)
Beyond the preview
Go deeper on NCT05347849.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05347849.